Annovis Bio (ANVS) vs BioStem Technologies (BSEM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioStem Technologies (BSEM) has outperformed Annovis Bio (ANVS) over the past year, losing 45.0% versus a loss of 48.5%. Over five years, BSEM leads with a +88.6% price change compared with -95.8% for ANVS. Annovis Bio is the larger company by market cap ($49.9 million vs $49.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANVS | BSEM |
|---|---|---|
| Share price | $1.17 | $2.64 |
| Market cap | $49.93M | $49.29M |
| 1-day change | -3.31% | +10.46% |
| YTD return | -66.18% | -30.71% |
| 1-year return | -48.46% | -45.00% |
| 5-year return | -95.82% | +88.57% |
| P/E ratio (TTM) | — | 3.00 |
| Forward P/E | — | 9.10 |
| EPS (TTM) | $-1.75 | $0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.50 | $8.40 |
| 52-week low | $1.04 | $2.25 |
| Distance from 52-week high | -78.73% | -68.57% |
| Analyst consensus | none | none |
| Avg. price target upside | +797.44% | +165.15% |
| Average volume | 884.63K | 124.14K |
| Shares outstanding | 42.68M | 18.67M |
| Employees | 7 | 73 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Annovis Bio
ANVS stock →Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Healthcare · Biotechnology · 7 employees
About BioStem Technologies
BSEM stock →BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
Healthcare · Biotechnology · 73 employees
ANVS vs BSEM FAQ
Which is bigger, Annovis Bio or BioStem Technologies?
Annovis Bio (ANVS) is larger, with a market capitalization of $49.93M compared with $49.29M for BioStem Technologies (BSEM).
Which stock has performed better over the past year, ANVS or BSEM?
BSEM returned -45.00% over the past 12 months, compared with -48.46% for ANVS (price return, excluding dividends). Past performance does not predict future results.
Are Annovis Bio and BioStem Technologies in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.